| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | CVS43XG1L5 |
| InChI Key | JACAAXNEHGBPOQ-LLVKDONJSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C19H19N3O3 |
| Molecular Weight | 337.38 |
| AlogP | 2.54 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 1.0 |
| Polar Surface Area | 77.15 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 25.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Glutamate receptor ionotropic, AMPA 1 antagonist | PubMed |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Amyotrophic Lateral Sclerosis | 2 | D000690 | ClinicalTrials |
| Epilepsy | 2 | D004827 | ClinicalTrials |
| Glioblastoma | 2 | D005909 | ClinicalTrials |
| Oligodendroglioma | 2 | D009837 | ClinicalTrials |
| Astrocytoma | 2 | D001254 | ClinicalTrials |
| Oligodendroglioma | 2 | D009837 | ClinicalTrials |
| Parkinson Disease | 2 | D010300 | ClinicalTrials |
| Central Nervous System Neoplasms | 2 | D016543 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 161832-65-1 |
| ChEBI | 34992 |
| ChEMBL | CHEMBL61872 |
| DrugBank | DB04982 |
| EPA CompTox | DTXSID10167259 |
| FDA SRS | CVS43XG1L5 |
| Guide to Pharmacology | 8279 |
| KEGG | C13670 |
| PubChem | 164509 |
| SureChEMBL | SCHEMBL118011 |
| ZINC | ZINC000003823565 |